Long-acting preparations of exenatide

Long-acting preparations of exenatide

Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA),...

Full description

Bibliographic Details
Main Authors:	Cai, Yunpeng, Wei, Liangming, Ma, Liuqing, Huang, Xiwen, Tao, Anqi, Liu, Zhenguo, Yuan, Weien
Format:	Online
Language:	English
Published:	Dove Medical Press 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771853/

Similar Items

Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion
by: Hong, Xiaoyun, et al.
Published: (2013)

Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes
by: Cai, Yunpeng, et al.
Published: (2014)

Advances with microRNAs in Parkinson’s disease research
by: Ma, Liuqing, et al.
Published: (2013)

Porous microsphere and its applications
by: Cai, Yunpeng, et al.
Published: (2013)

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone
by: Hu, Zhenhua, et al.
Published: (2012)

Surgical wound healing using hemostatic gauze scaffold loaded with nanoparticles containing sustained-release granulocyte colony-stimulating factor
by: Yuan, Weien, et al.
Published: (2011)

Controlled-release and preserved bioactivity of proteins from (self-assembled) core-shell double-walled microspheres
by: Yuan, Weien, et al.
Published: (2012)

Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine
by: Hong, Xiaoyun, et al.
Published: (2013)

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
by: Yang, Xinxin, et al.
Published: (2012)

Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate
by: Zhang, Baojie, et al.
Published: (2014)

pH-sensitive degradable nanoparticles for highly efficient intracellular delivery of exogenous protein
by: Xu, Dan, et al.
Published: (2013)

Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson’s Disease
by: Chen, Wei, et al.
Published: (2016)

Microneedles As a Delivery System for Gene Therapy
by: Chen, Wei, et al.
Published: (2016)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
by: Simó, Rafael, et al.
Published: (2015)

Evolution of Exenatide as a Diabetes Therapeutic
by: Bhavsar, Sunil, et al.
Published: (2013)

Evaluation of the stability of exenatide in aqueous solutions
by: Al Assadi, Ali
Published: (2015)

Effect of renal impairment on the pharmacokinetics of exenatide
by: Linnebjerg, Helle, et al.
Published: (2007)

NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and â-arrestin-1 expression in parkinsonian rats
by: Wu, Na, et al.
Published: (2013)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
by: Edwards, Krystal L., et al.
Published: (2006)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
by: Ji, Linong, et al.
Published: (2013)

Development of dextran nanoparticles for stabilizing delicate proteins
by: Wu, Fei, et al.
Published: (2013)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
by: Zhao, Ruiying, et al.
Published: (2011)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
by: Kyriacou, Angelos, et al.
Published: (2010)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice†
by: Tatarkiewicz, K, et al.
Published: (2014)

Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
by: Che, Junyi, et al.
Published: (2016)

Long-acting Preparations in Substance Abuse Management: A Review and Update
by: Hegde, Aditya, et al.
Published: (2013)

Spontaneous intercalation of long-chain alkyl ammonium into edge-selectively oxidized graphite to efficiently produce high-quality graphene
by: Wei, Liangming, et al.
Published: (2013)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
by: Henry, Robert R., et al.
Published: (2013)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
by: Ridge, T, et al.
Published: (2012)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
by: Blevins, Thomas, et al.
Published: (2016)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects
by: Darpö, Börje, et al.
Published: (2013)

Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction
by: Cao, Yuan-Yuan, et al.
Published: (2015)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
by: Inagaki, Nobuya, et al.
Published: (2011)

G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts
by: Zoso, Alessia, et al.
Published: (2016)

Preparation of bioactive interferon alpha–loaded polysaccharide nanoparticles using a new approach of temperature-induced water phase/water-phase emulsion
by: Liu, Guang, et al.
Published: (2012)

Are we prepared for the Mental Capacity Act?
by: Jane, Cowan
Published: (2007)

Advances with RNA interference in Alzheimer’s disease research
by: Chen, Shun, et al.
Published: (2013)

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
by: Yang, Xinxin, et al.
Published: (2012)

Biscarbamate cross-linked low molecular weight Polyethylenimine polycation as an efficient intra-cellular delivery cargo for cancer therapy
by: Ge, Xuemei, et al.
Published: (2014)

Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6-hydroxydopamine-induced rat model
by: QI, CHEN, et al.
Published: (2014)